OPTHEA LTD-SPON ADR
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About OPT
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Find out what a historical investment in OPTHEA LTD-SPON ADR would be worth today using our OPT stock calculator.
$483.38M
-
0.00%
0
$0.00
$0.00
$0.00
$6.30
$2.02
Ready to start your investing journey with Stake?
Open an accountOPT FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in OPT
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in OPT
on Stake
Buy OPT from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of OPT from only US$10 with fractional shares
